Dr. Hamid on the Evolution of Precision Medicine in Prostate Cancer

Anis Hamid, MBBS
Published: Thursday, Apr 02, 2020



Anis Hamid, MBBS, genitourinary oncology research fellow, Dana-Farber Cancer Institute, discusses the evolution of precision medicine in prostate cancer.

It is exciting to see precision medicine truly take hold in prostate cancer, says Hamid. Historically, clinically driven parameters such as volume of metastatic disease were used to indicate which subpopulations of patients benefit from chemotherapy versus those that do not. Now, the field can use biological parameters to guide more precise treatment decisions.

Precision medicine is becoming more apparent across oncology with the use of clinical information, biological information, and drug response information, among other things, concludes Hamid.
SELECTED
LANGUAGE


Anis Hamid, MBBS, genitourinary oncology research fellow, Dana-Farber Cancer Institute, discusses the evolution of precision medicine in prostate cancer.

It is exciting to see precision medicine truly take hold in prostate cancer, says Hamid. Historically, clinically driven parameters such as volume of metastatic disease were used to indicate which subpopulations of patients benefit from chemotherapy versus those that do not. Now, the field can use biological parameters to guide more precise treatment decisions.

Precision medicine is becoming more apparent across oncology with the use of clinical information, biological information, and drug response information, among other things, concludes Hamid.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x